Blog

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines/Instagram

Apr 24, 2025, 11:06

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma – BeOne Medicines

BeOne Medicines shared a post on LinkedIn:

“The FDA has approved new dosing options for our PD-1 inhibitor in both first- and second-line esophageal squamous cell carcinoma (ESCC) and first-line gastric cancer, providing more flexibility for pairing our immunotherapy with the most common chemotherapy regimens.

This approval reinforces our dedication to patients in the U.S. living with upper GI cancers—helping to expand access to personalized treatment approaches and supporting providers in delivering care that fits the unique needs of each patient.”

New dosing options for PD-1 inhibitor in first and second-line esophageal squamous cell carcinoma - BeOne Medicines

BeOne Medicines cancer chemotherapy ESCC esophageal squamous cell carcinoma FDA fight against cancer GI cancers Global fight against cancer immunotherapy OncoDaily Oncology PD-1 inhibitor

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book